Acurx Pharmaceuticals Q3 2026 Earnings Date & Estimates

Acurx Pharmaceuticals (NASDAQ:ACXP) (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on antibacterial compounds designed to address pathogens that are increasingly resistant to existing treatments.

Acurx’s lead product candidate is ibezapolstat, an investigational antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile or C. diff infection. Ibezapolstat is designed to work through a differentiated mechanism that targets bacterial DNA polymerase IIIC, an enzyme involved in bacterial DNA replication. The company has also evaluated the compound’s potential effects on the gut microbiome, which may be relevant to the recurrence of C. difficile infection.

Acurx does not have marketed products and is focused on advancing its pipeline through clinical development and regulatory evaluation. Its activities are primarily directed toward the United States and other markets where its clinical and regulatory programs are conducted. As a development-stage company, Acurx’s future prospects depend on the results of clinical trials, regulatory approvals and its ability to obtain funding or strategic support for continued development.